جست‌وجوی استاد و پژوهشگر

Mitch McVeyمشاهده پروفایل

استاد

• DNA Repair
• DNA Damage Tolerance
• Molecular Biology
• +۳ مورد دیگر

Mitch McVey is a Professor of Biology and a member of the Graduate Biomedical Sciences program at Tufts University, School of Arts and Sciences. His research focuses on DNA repair mechanisms in Drosophila, particularly alternative end joining and damage tolerance pathways. He leads a lab with a team of researchers including PhD students, postdocs, and undergraduates. McVey has held academic positions at Tufts since 2005, progressing from Assistant to Associate Professor before becoming a full Professor in 2017. Education: PhD in Biology from MIT (2001), BA in Molecular, Cellular, and Developmental Biology from University of Colorado Boulder (1994). Research: Investigates DNA repair pathways, including mechanisms of double-strand break repair and the role of DNA polymerase theta. Collaborates on projects involving gut microbiome effects on lifespan, DNA damage as a stress biomarker in birds, and antioxidant responses to antidepressants. His lab's research highlights error-prone repair pathways' roles in cancer and aging. Key findings include identifying polymerase theta's role in alternative end joining and demonstrating translesion synthesis as a primary damage tolerance strategy in rapidly dividing tissues. Current projects explore REV1’s regulatory roles and interventions to enhance healthspan. Grants & Awards: Funded by NIH, NSF, and Ellison Foundation. Recognitions include AAAS Fellowship (2023), Lerman-Neubauer Teaching Prize (2020), and Tufts Mentoring Awards. His work spans genetics, molecular biology, and interdisciplinary collaborations with ecology and microbiology. Labs & Teams: Leads the McVey Lab at Tufts, co-directs the IRACDA postdoctoral training program, and collaborates with labs at Boston University and other institutions on healthspan extension and stress biomarker studies.

Yuliang Wuمشاهده پروفایل

استاد

• Cancers
• Genetic disorders
• Genome stability
• +۳ مورد دیگر

Dr. Yuliang Wu is a Professor of Biochemistry at the University of Saskatchewan, specializing in DNA repair mechanisms and genomic stability. He holds a Ph.D. from the International Centre for Genetic Engineering and Biotechnology (ICGEB), India, and completed postdoctoral training at the University of Alberta and NIH. His research focuses on helicases (FANCJ, ChlR1, RTEL1) and their roles in cancer, genetic disorders, and aging. Key areas include G-quadruplex resolution, innate immunity activation via DDX41, and synthetic lethality targets in cancer therapy. Research Interests: Cancers linked to DNA repair defects (breast, ovarian), genetic syndromes (Fanconi anemia, Warsaw breakage), helicase functions in replication stress, and immune responses to viral DNA. Current projects involve DDX43's role in mRNA splicing and RTEL1's telomere regulation. Publications emphasize helicase biochemistry, synthetic lethality in cancer, and mechanistic insights into DNA repair pathways. Collaborations include functional studies on FANCJ's role in resolving replication barriers and DDX41's cGAS-STING activation during viral infection.

Gerardo Ferbeyreمشاهده پروفایل

استاد

• Developmental Biology
• Senescence and Cancer
• Molecular Biology
• +۳ مورد دیگر

Dr. Gerardo Ferbeyre is a Full Professor at the University of Montreal's Faculty of Medicine, Department of Biochemistry and Molecular Medicine. His research focuses on cellular senescence, cancer biology, and molecular mechanisms of aging, particularly how oncogenes and DNA damage activate senescence pathways. He leads a multidisciplinary team investigating senescence-associated secretory phenotypes, ribosomal stress, and therapeutic targets like metformin and senolytics. Collaborations include the Research Center of the University of Montreal Hospital Center (CRCHUM) and the AIDS and Infectious Diseases Network (AIDS/ID). Key areas include senescence's role in cancer suppression, metabolic reprogramming, and senolytic drug development. His work bridges basic science with clinical implications in oncology and aging. Research Themes: Senescence Biology, Oncogene-Induced Stress, PML Nuclear Bodies Techniques: Molecular biology, cell signaling analysis, drug screening Recent studies highlight senescence’s connection to mitochondrial function, ribosome biogenesis defects, and how metabolic pathways like NAD+ regulation influence senescence bypass. His lab explores translational research, including biguanide-PROTACs for pancreatic cancer and senolytic therapies for age-related diseases. Key collaborations include work with Professors François Major (miRNA engineering), Ivan Topisirovic (metabolism), and Michael Pollak (metformin studies). Funding includes grants from the Canadian Institutes of Health Research and industry partnerships.

• Genome Instability
• DNA Repair Mechanisms
• Chromosome Bridges
• +۶ مورد دیگر

Teresa Anglada Pons is a Researcher in the Department of Cellular Biology, Physiology and Immunology at the Universitat Autònoma de Barcelona's Faculty of Biosciences. She specializes in molecular mechanisms of genome instability, particularly focusing on chromosome bridge resolution, DNA repair pathways, and the application of CRISPR/Cas9 technology to study mitotic processes. Her research interests center on understanding how chromatin bridges form and resolve during cell division, and how defects in these processes lead to genome instability. She investigates the roles of key proteins like BRCA1 and 53BP1 in DNA repair mechanisms, with particular attention to age-related changes in these pathways. Her work bridges fundamental cell biology with potential clinical implications for cancer research and radiation biology. Dr. Anglada Pons has been actively involved in multiple significant research projects since 2012, including studies on Serbian children exposed to radiation, mammography risk assessment, and chromatin bridge resolution mechanisms funded by organizations including Fundació La Marató de TV3, Consejo de Seguridad Nuclear, European Commission, and Institute of Health Carlos III. Her scholarly contributions include multiple peer-reviewed publications in high-impact journals such as International Journal of Molecular Sciences, FASEB Journal, Seminars in Cell and Developmental Biology, Frontiers in Cell and Developmental Biology, and Aging. Her work has garnered substantial attention in the scientific community with citations across multiple platforms. She completed her doctoral training in 2018 with a thesis examining the contribution of BRCA1 and 53BP1 to DNA break repair, supervised by Dr. Anna Genescà and Dr. Martín Flix. Her ongoing research continues to explore the intricate relationship between DNA repair mechanisms, chromosome segregation, and genome stability.

• Genome Integrity
• Cell Biology
• Molecular Biology
• +۴ مورد دیگر

**Roles & Affiliations:** A. Genescà holds a PhD in Sciences from Universitat Autònoma de Barcelona (UAB) and has served as Profesora Titular (Associate Professor) at UAB from 1994 to 2011. She has led and contributed to 17 research projects, including the 'Chromatin bridge resolution and generation of unstable genomes' (2020–2024). Her work addresses genome integrity, DNA damage, and cancer mechanisms. Education: PhD in Sciences (UAB, 1988), Degree in Sciences (UAB, 1982) **Research Interests:** Focus on genome stability, chromosomal abnormalities, telomere biology, and DNA repair mechanisms. Her studies explore how defects in nuclear envelope dynamics and chromosome bridges contribute to genomic instability in cancer. **Projects & Awards:** Principal Investigator in projects funded by the European Commission and Fundació La Marató de TV3. Recognized with Becaria FPI and Becaria CAICYT fellowships. **Advising & Grants:** Supervised 12 theses and contributed to collaborative cancer research networks (ISCIII grants). **Labs & Teams:** Leads the Genome Integrity and Reproductive Biology lab at UAB, collaborating with teams on chromosome dynamics and radiation effects.

Stefan Meyerمشاهده پروفایل

مدرس ارشد

• Paediatric Oncology
• Genetic Disorders
• DNA Damage Response
• +۳ مورد دیگر

Stefan Meyer is a Senior Lecturer and Honorary Consultant Paediatric Oncologist at the University of Manchester, affiliated with Royal Manchester Children’s Hospital and Christie NHS Foundation Trust. He leads care for children with Fanconi anaemia, Bloom syndrome, and other Chromosomal Instability Syndromes. His research focuses on malignant transformation in genetic disorders and the DNA damage response, particularly in AML cell lines linked to FANCD1/BRCA2 defects. He collaborates with Dr. Christine Schmidt in the Genome Stability Lab. Teaching roles include Academic Lead for European Studies at Manchester Medical School, supervision of PhD/MD/MRes students, and clinical paediatric oncology training. Research: Explores EVI1 oncogene amplification in FA-derived AML, systems biology approaches to DNA repair pathways, and therapeutic targets. Collaborations: Ongoing projects with Dr. Schmidt on paediatric and syndrome-associated cancers. Research interests align with UN SDG 3 (Good Health and Well-being). Key platforms include Cancer Manchester and the Manchester Cancer Research Centre.

Xu Pengمشاهده پروفایل

دانشیار

• Cardiovascular Development
• Genetic Mechanisms of Disease
• Molecular Biology
• +۴ مورد دیگر

Xu Peng is an Associate Professor in the Department of Medical Physiology at Texas A&M University's School of Medicine. His research focuses on cardiovascular development and disease mechanisms, particularly exploring the role of Cdc42 in vasculogenesis, angiogenesis, and heart development. He leads a lab investigating genetic and molecular pathways involved in cardiovascular conditions such as heart failure and hypertension. Education: Shanghai Tiedao Medical College (MD, 1992), Shanghai Second Medical University (MS, 1997), Peking University (PhD, 2000). Key research areas include: Cdc42 regulation in cardiovascular systems miRNA biogenesis and epigenetic regulation Angiogenesis and lymphatic development Epigenetic mechanisms in heart disease His lab members include Patrick DeSpain (Technician I) and Reed Rivera (Student Research Assistant). Ongoing projects involve mouse genetic models to study Cdc42's role in cardiomyocyte function and vascular integrity. Publications span molecular mechanisms of miRNA regulation, Cdc42's role in embryonic development, and cardiovascular disease pathophysiology. His work bridges basic science and translational medicine to address unmet clinical needs in cardiovascular care.

Mendell Rimerمشاهده پروفایل

دانشیار

• Neuroscience
• Molecular Biology
• Neurobiology
• +۳ مورد دیگر

Mendell Rimer, PhD, is an Associate Professor in the Department of Neuroscience & Experimental Therapeutics at Texas A&M University's School of Medicine. His research focuses on molecular and cellular mechanisms of synapse formation, maintenance, and pathology using the neuromuscular junction (NMJ) as a model system. He employs mouse molecular genetics combined with molecular, cellular, and immunological techniques. Education: BS in Biology, Universidad de Los Andes PhD in Molecular and Cell Biology (with Pharmacology minor), University of Maryland, Baltimore Postdoctoral Training: Neurobiology and Molecular Genetics at Stanford University & New York University Research interests include synaptic plasticity, neuromuscular junction pathology in neurodegenerative diseases (e.g., ALS, Duchenne muscular dystrophy), and signaling pathways involving MAP kinases and neuregulins. His work combines genetic models with advanced imaging and molecular biology techniques. Publications span synaptic development, neuromuscular disorders, and signaling mechanisms. Notable work includes studies on lymphatic dysfunction in ALS models and roles of ERK kinases in muscle maintenance. Active in graduate training through the Interdisciplinary Program in Neuroscience and Medical Science PhD program. Labs/Teams: The Rimer Lab focuses on integrative approaches to neuromuscular synapse biology. Collaborations involve clinical translation of synaptic repair mechanisms in neurodegenerative diseases.

Jonathan Corcoranمشاهده پروفایل

استاد

• Neuroscience
• Neurodegenerative Diseases
• Retinoic Acid Signaling
• +۵ مورد دیگر

Professor Jonathan Corcoran is a faculty member at King's College London, specifically in the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) as a Professor of Molecular Neurobiology. His research focuses on discovering drugs for central nervous system (CNS) disorders, including Alzheimer’s disease, motoneuron disease, traumatic brain injury, spinal cord injury (SCI), and neuropathic pain. His work centers on retinoic acid (RA) signaling pathways, particularly the retinoic acid receptors (RARs alpha, beta, gamma), with a translational focus on developing RARβ agonists for clinical applications. Key achievements include the development of the orally available RARβ drug KCL 286, which is in Phase II clinical trials for SCI. His research spans drug design, neuroprotection, axonal regeneration, and neuroinflammation modulation. He leads major projects funded by organizations such as the Wellcome Trust, MRC, and NIHR, including a Phase IIA trial for spinal cord injury treatment. His academic roles include affiliations with the Wolfson Sensory, Pain and Regeneration Centre and the NIHR Maudsley Biomedical Research Centre (BRC). He has supervised multiple students and contributed to over 34 peer-reviewed publications, with a focus on mechanisms of neural repair, retinoic acid signaling, and drug efficacy in CNS disorders. His work aligns with UN Sustainable Development Goals related to health and innovation in medicine. Key collaborations include work on exosome-mediated signaling, mitochondrial dynamics, and the role of RARβ in modulating PTEN activity for spinal cord regeneration. His research bridges basic science and clinical translation, aiming to address unmet medical needs in neurodegenerative and traumatic CNS conditions.

Jennifer Puckمشاهده پروفایل

استاد

• Immunology
• Primary Immunodeficiencies
• Severe Combined Immunodeficiency (SCID)
• +۵ مورد دیگر

Dr. Jennifer Puck is a Professor of Pediatrics at the University of California San Francisco (UCSF) School of Medicine. She directs the UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies and serves as Principal Investigator of the NIH-funded Primary Immune Deficiency Treatment Consortium (PIDTC). Education: Harvard University, Cambridge, MA, BA cum laude, 1971, Biochemistry Harvard Medical School, Boston, MA, MD, 1975, Medicine Dr. Puck's research focuses on human immune disorders and mouse models of lymphocyte development. She has pioneered the use of genetic and genomic technology along with cellular immunology to study impaired lymphocyte development and immune dysregulation. Her work has led to significant breakthroughs in understanding and treating primary immunodeficiencies, particularly severe combined immunodeficiency (SCID). Her research publications demonstrate a strong focus on primary immunodeficiencies, particularly SCID and chronic granulomatous disease. Her work spans basic science, translational research, and clinical applications, with recent emphasis on newborn screening, gene therapy, and hematopoietic cell transplantation outcomes. Scientific Awards and Honors: Abbot Award in Clinical and Diagnostic Immunology from the American Society of Microbiology (2013) Colonel Harlan Sanders Award for Lifetime Achievement in Genetics from the March of Dimes (2014) Boyle Achievement Award for service to primary immunodeficiencies from the Immune Deficiency Foundation (2017) Physician Scientist Award, NIH (1984-89) Ethyl Brown Foerderer Scholar, Children's Hospital of Philadelphia (1986-89) NHGRI Director's Award for Studies Defining Autoimmune Lymphoproliferative Syndrome (1995, 97, 98, 99) NHGRI Director's Awards for Scientific Achievement and Outstanding Service (2001) Member, American Society of Clinical Investigation (ASCI) Member, Society for Pediatric Research (SPR) Member, Association of American Physicians (AAP) Member, American Pediatric Society (APS) Member, National Academy of Medicine Dr. Puck has mentored numerous trainees and researchers in immunology and primary immunodeficiency disorders. Her current research is supported by multiple NIH grants including "Inherited T cell defects: Diagnosis, Mechanisms and Treatments" and the "Primary Immunodeficiency Treatment Consortium (PIDTC)." She also leads a CIRM-funded project on gene therapy for Artemis-deficient SCID. Dr. Puck directs the UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies and serves on the Medical Advisory Committee of the Immune Deficiency Foundation and the Committee on Primary Immunodeficiency Disease of the International Union of Immunological Societies.

Zijun Wangمشاهده پروفایل

دانشیار

• Neuropharmacology
• Epigenetics
• Drug Addiction
• +۳ مورد دیگر

Zijun Wang is an Associate Professor in the Department of Pharmacology & Toxicology at the University of Kansas School of Pharmacy. She holds a Ph.D. in Pharmacology from Peking University and completed postdoctoral training at the State University of New York at Buffalo. Her research focuses on neuropharmacology, epigenetics, and brain disorders such as drug addiction and autism. University of Kansas School of Pharmacy Department of Pharmacology & Toxicology Email: zjwang@ku.edu Her work explores how environmental factors like stress and drug exposure alter brain reward pathways, leading to disease states. Using multidisciplinary approaches—including behavioral studies, molecular biology, and in vivo calcium imaging—she investigates epigenetic mechanisms and neural circuits in disorders like opioid addiction and autism. A central theme is identifying novel therapeutic targets through interventions in histone modification, DNA repair, and synaptic function. Recent publications highlight neuroadaptations in prefrontal cortex and nucleus accumbens, sex-specific effects of social isolation, and the role of growth factors like IGF-1 in addiction vulnerability. Her studies frequently employ mouse models of autism and cocaine/opiate addiction to link molecular changes to behavioral outcomes. She leads the Wang Lab , focusing on translational neuroscience and pharmacotherapies for brain disorders. Collaborations span institutions like SUNY Buffalo and Peking University, with techniques such as chemogenetics and transgenic mice to dissect pathophysiological mechanisms.

• Mitochondrial Biology
• Mitochondrial DNA Disorders
• Neurodegenerative Diseases
• +۳ مورد دیگر

Dr. Amy Vincent is a researcher at Newcastle University, specializing in mitochondrial biology and its implications in human disease. Her work focuses on mitochondrial DNA disorders, oxidative phosphorylation defects, and neurodegenerative conditions like Parkinson’s disease. Research trends in her publications include: Mitochondrial morphology and function in disease pathology Metabolic pathways (e.g., serine biosynthesis) in mitochondrial protection Advanced imaging techniques (SBF-SEM, mass cytometry) for mitochondrial analysis Mechanisms of mtDNA replication and deletion formation Her collaborations span multidisciplinary teams in mitochondrial medicine, with a strong emphasis on translational research for diagnostic and therapeutic applications.

• Primary Immunodeficiency
• Innate Immunity
• Antimicrobial peptides
• +۴ مورد دیگر

Emilie Wahren Borgström is a researcher affiliated with the Department of Laboratory Medicine at Karolinska Institutet, specializing in clinical immunology. She is part of the Division of Clinical Immunology at Labmed and works within the Primary Immunodeficiency, Innate Immunity and Antimicrobial peptides research group led by Peter Bergman (The AMP-group). Her educational background includes: PhD (Doctor of Philosophy) from the Department of Medicine, Solna, Karolinska Institutet (2019) Medical Degree from Karolinska Institutet (1995) Dr. Wahren Borgström's research focuses on primary immunodeficiency disorders, innate immunity, and antimicrobial peptides. Her work particularly examines immune responses in patients with various immunodeficiencies, including responses to vaccines and infections. She has conducted significant research on tuberculosis immunology, investigating diagnostic markers for active and latent TB infection. Her doctoral thesis (2018) focused on "Evaluation of immunological markers for the diagnosis of active and latent tuberculosis." She has also explored vitamin D supplementation effects in immunodeficient patients and immune responses to infectious diseases like tuberculosis and tick-borne encephalitis. Her recent publications demonstrate a strong focus on immunological responses to SARS-CoV-2 vaccines in immunocompromised patients, particularly those with primary immunodeficiencies. She has published extensively on how different immunodeficiency conditions affect vaccine efficacy, with particular attention to B cell responses and T cell immunity. Her work also spans tuberculosis diagnostics, vitamin D supplementation in immunodeficient patients, and STAT1 gain-of-function disorders, showing a consistent pattern of research addressing clinical immunology challenges in vulnerable patient populations. Her scientific recognition includes: CIMED grant 2026-2028 Dr. Wahren Borgström collaborates extensively with researchers across Karolinska Institutet and has been involved in multiple clinical trials examining vaccine responses in immunocompromised populations. Her work often involves interdisciplinary teams combining clinical immunology, molecular biology, and infectious disease expertise. She has co-authored studies with prominent researchers including Peter Bergman, Charlie Sullivan IE Smith, and members of the immunology community at Karolinska. She is an active member of the Peter Bergman Research Group (The AMP-group), which provides a strong foundation for her investigations into immune responses in various patient populations. Her research has direct clinical implications for vaccination strategies in immunocompromised patients and diagnostic approaches for infectious diseases in this vulnerable population.

• cancer metastasis
• pancreatic cancer biology
• metastasis-initiating cells
• +۵ مورد دیگر

Christina M. Ferrer, PhD, is a tenure-track Assistant Professor of Pharmacology & Physiology at the University of Maryland, Baltimore, with a joint appointment at the Greenebaum Comprehensive Cancer Center. Her laboratory, the Ferrer Lab, is dedicated to understanding and combating metastatic pancreatic cancer. Education BS, Biological Sciences, University of Central Florida, 2007 MS, Biomedical Sciences, Barry University, 2009 PhD, Molecular & Cell Biology & Genetics, Drexel University College of Medicine, 2015 Postdoctoral Study, Massachusetts General Hospital Cancer Center & Harvard Medical School, 2020 Instructor in Medicine, Massachusetts General Hospital Cancer Center & Harvard Medical School, 2022 Research Focus Dr. Ferrer’s research centers on the cellular and molecular mechanisms governing metastatic initiation, dissemination, and outgrowth, with a particular emphasis on pancreatic cancer. Using integrative genetic, pharmacological, in-vitro and in-vivo models, her group investigates how intrinsic cellular programs and the tumor microenvironment cooperate to promote metastatic survival. Key themes include metabolic reprogramming, post-translational O-GlcNAcylation, redox homeostasis, and the identification of actionable therapeutic targets against disseminated tumor cells and chemo-resistant metastases. Across her 2011–2025 publication record, a clear trajectory emerges from early mechanistic studies on O-GlcNAc transferase and SIRT1 in prostate and breast cancers to recent high-impact work elucidating the role of glutathione S-transferase Gstt1 as a driver of pancreatic cancer metastasis and stemness. The collective body of work situates her at the intersection of cancer metabolism, epigenetic regulation, and translational oncology. Scientific Recognition Dr. Ferrer has co-authored multiple seminal papers in journals such as Nature Cell Biology , Genes & Development , Molecular Cell , and Oncogene . Her 2018 Genes & Development paper was selected for the issue’s cover image, underscoring its impact. Laboratory & Team The Ferrer Lab is housed within the Bressler Research Building (Room 10-039) on the UMB campus. The team employs cutting-edge techniques in metabolomics, genome editing, intravital imaging, and patient-derived models to accelerate discovery and therapeutic development against metastatic pancreatic cancer.

• Genomics
• Antibiotic Resistance
• Breast Cancer Biology
• +۵ مورد دیگر

Assoc Professor Peadar Ó Gaora is a faculty member at the School of Biomolecular and Biomedical Science , University College Dublin, and affiliated with the Conway Institute . Holding a PhD from Trinity College Dublin , he has contributed extensively to microbial genomics, endocrine resistance in breast cancer, and placental transcriptomics. BA, Trinity College Dublin MSc, Imperial College London PhD, Trinity College Dublin His research spans genomic characterization of pathogens (e.g., Rhodococcus soli, Clostridium estertheticum), epigenetic regulation in cancer (SRC-1 repression mechanisms), and diet-gene interactions in diabetes via NLRP3 inflammasome studies. Methodologically, he employs hybrid sequencing approaches and transcriptomic network analysis to dissect disease mechanisms. Recent publications highlight 15 articles since 2011, with a 2024 study on the complete genome of saprophytic Rhodococcus species and 2019 work on hyperglycemia-hypoxia synergy in macrophage inflammation. His 2016 research on Clostridium estertheticum provides genomic insights into meat spoilage, while 2015 studies address endocrine-resistant breast cancer and transforming growth factor signaling . Teaching activities include coordination of modules such as Genetics Research Project and Programming for Biologists since 2017, with a focus on integrating computational methods into biomolecular education.